VarmX will use the combination of a €7.5m Series A financing co-led by BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter plus an €5m innovation credit from  the Netherlands Enterprise Agency (RVO.nl) to develop a modified blood coagulation factor X to prevent severe bleeding in haemophilia patients.